Investors

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
More>>
Featured Reports
2016 Annual Report on Form 10-K - PDF 2016 Annual Report on Form 10-K
Fact Sheet - PDF Fact Sheet
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$17.46
Change (%) Stock is Up 0.06 (0.34%)
Volume515,123
Data as of 12/13/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
12/08/17OraSure Technologies Announces 2018 Annual Meeting Date
BETHLEHEM, Pa., Dec. 08, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2018 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 8, 2018.  This will be a completely virtual meeting, conducted as a live webcast.  Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of p... 
Printer Friendly Version
11/30/17OraSure Technologies Supports World AIDS Day With Innovative Programs to Enable HIV Testing
BETHLEHEM, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced several new HIV testing-related initiatives, in recognition of World AIDS Day.  OraSure is working with The AIDS Institute to launch a grant program to encourage the development of innovative HIV self testing programs and collaborating with both The AIDS Institute and Walgreens to promote rapid HIV testing in cit... 
Printer Friendly Version
11/02/17OraSure Technologies to Present at the 2017 Canaccord Genuity Medical Technologies & Diagnostics Forum
BETHLEHEM, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2017 Canaccord Genuity Medical Technologies and Diagnostics Forum.  The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on November 9, 2017, at approximately 8:00 AM Eastern ... 
Printer Friendly Version
11/01/17OraSure Announces 2017 Third Quarter Financial Results
BETHLEHEM, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and nine months ended September 30, 2017. Financial Highlights Consolidated net revenues for the third quarter of 2017 were $42.3 million, a 31% increase from the third quarter of 2016. Consolidated net product revenues were $41.2 million, representing a 62% ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/08/18 10:00 a.m. ET
OraSure Technologies, Inc. 2018 Annual Meeting of Stockholders
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet